These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34205099)

  • 1. Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.
    Iwamoto H; Shimose S; Noda Y; Shirono T; Niizeki T; Nakano M; Okamura S; Kamachi N; Suzuki H; Sakai M; Kajiwara A; Itano S; Tanaka M; Yamaguchi T; Kuromatsu R; Koga H; Torimura T; On Behalf Of The Kurume Liver Cancer Study Group Of Japan
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34205099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective Study.
    Takeda S; Namisaki T; Tsuji Y; Fujimoto Y; Murata K; Enomoto M; Fujinaga Y; Nishimura N; Kitagawa K; Takaya H; Kaji K; Inoue T; Kawaratani H; Akahane T; Mitoro A; Yoshiji H
    Anticancer Res; 2022 Nov; 42(11):5465-5473. PubMed ID: 36288892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
    Fulgenzi CAM; Cheon J; D'Alessio A; Nishida N; Ang C; Marron TU; Wu L; Saeed A; Wietharn B; Cammarota A; Pressiani T; Personeni N; Pinter M; Scheiner B; Balcar L; Napolitano A; Huang YH; Phen S; Naqash AR; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; Sharma R; Cortellini A; Gaillard VE; Chon HJ; Pinato DJ
    Eur J Cancer; 2022 Nov; 175():204-213. PubMed ID: 36148739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
    Rimini M; Persano M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Yoo C; Lonardi S; Piscaglia F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Pressiani T; Montes M; Vivaldi C; Soldà C; Hiraoka A; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Burgio V; Rimassa L; Scartozzi M; Cascinu S; Casadei-Gardini A
    Target Oncol; 2023 Mar; 18(2):221-233. PubMed ID: 36920648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.
    Qin S; Ren Z; Feng YH; Yau T; Wang B; Zhao H; Bai Y; Gu S; Li L; Hernandez S; Xu DZ; Mulla S; Wang Y; Shao H; Cheng AL
    Liver Cancer; 2021 Jul; 10(4):296-308. PubMed ID: 34414118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice.
    Ando Y; Kawaoka T; Kosaka M; Shirane Y; Johira Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Kosaka Y; Uchikawa S; Kodama K; Fujino H; Nakahara T; Ono A; Murakami E; Yamauchi M; Okamoto W; Takahashi S; Imamura M; Chayama K; Aikata H
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort.
    Jost-Brinkmann F; Demir M; Wree A; Luedde T; Loosen SH; Müller T; Tacke F; Roderburg C; Mohr R
    Aliment Pharmacol Ther; 2023 Jun; 57(11):1313-1325. PubMed ID: 36883351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.
    Hayakawa Y; Tsuchiya K; Kurosaki M; Yasui Y; Kaneko S; Tanaka Y; Ishido S; Inada K; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Okamoto R; Izumi N
    Invest New Drugs; 2022 Apr; 40(2):392-402. PubMed ID: 34586531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study.
    Charonpongsuntorn C; Tanasanvimon S; Korphaisarn K; Payapwattanawong S; Siripoon T; Pakvisal N; Juengsamarn J; Phaibulvatanapong E; Chindaprasirt J; Prasongsook N; Udomdamrongkul K; Ngamphaiboon N; Sirachainan E
    JCO Glob Oncol; 2022 Nov; 8():e2200205. PubMed ID: 36455172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kudo M;
    Cancer Rep (Hoboken); 2022 Feb; 5(2):e1464. PubMed ID: 34114752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
    Xin Y; Cao F; Yang H; Zhang X; Chen Y; Cao X; Zhou X; Li X; Zhou J
    Front Immunol; 2022; 13():929141. PubMed ID: 35990634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.
    Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Rimassa L; Presa J; Masi G; Yoo C; Lonardi S; Tovoli F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Pressiani T; Kawaguchi T; Montes M; Vivaldi C; Soldà C; Piscaglia F; Hiraoka A; Sho T; Niizeki T; Nishida N; Steup C; Iavarone M; Di Costanzo G; Marra F; Scartozzi M; Tamburini E; Cabibbo G; Foschi FG; Silletta M; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Cammarota A; Burgio V; Cascinu S; Casadei-Gardini A
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5591-5602. PubMed ID: 36509984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma.
    Unome S; Imai K; Takai K; Miwa T; Hanai T; Nishigaki Y; Hayashi H; Kochi T; Shimizu S; Nagano J; Iritani S; Suetsugu A; Shimizu M
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
    Nakagawa M; Inoue M; Ogasawara S; Maruta S; Okubo T; Itokawa N; Iino Y; Obu M; Haga Y; Seki A; Kikuchi Y; Kogure T; Yumita S; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Fujita N; Sakuma T; Kojima R; Kanzaki H; Koroki K; Taida T; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Itobayashi E; Atsukawa M; Koma Y; Azemoto R; Ito K; Mizumoto H; Shinozaki M; Kato J; Kato N
    Cancer; 2023 Feb; 129(4):590-599. PubMed ID: 36426410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
    Sho T; Suda G; Ogawa K; Kimura M; Kubo A; Tokuchi Y; Kitagataya T; Maehara O; Ohnishi S; Shigesawa T; Nakamura A; Yamada R; Ohara M; Kawagishi N; Natsuizaka M; Nakai M; Morikawa K; Furuya K; Baba M; Yamamoto Y; Suzuki K; Izumi T; Meguro T; Terashita K; Ito J; Miyagishima T; Sakamoto N
    Hepatol Res; 2021 Sep; 51(9):979-989. PubMed ID: 34245216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients.
    Chen YH; Chen YY; Wang JH; Hung CH
    Anticancer Res; 2023 Mar; 43(3):1377-1384. PubMed ID: 36854513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.
    Sinner F; Pinter M; Scheiner B; Ettrich TJ; Sturm N; Gonzalez-Carmona MA; Waidmann O; Finkelmeier F; Himmelsbach V; De Toni EN; Ben Khaled N; Mohr R; Fründt TW; Kütting F; Bömmel FV; Lieb S; Krug S; Bettinger D; Schultheiß M; Jochheim LS; Best J; Müller C; Keitel V; Venerito M
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.
    Tomonari T; Tani J; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Asahiro M; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Masaki T; Takayama T
    Cancer Med; 2023 Feb; 12(3):2646-2657. PubMed ID: 35964253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.